Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient

Abstract

A compound of formula (I) (wherein all symbols are as defined in the specification) and salt thereof, and peroxisome proliferator activated receptor regulator comprising thereof as active ingredient. Because a compound of formula (I) have an activity of regulating peroxisome proliferator activated receptor regulator, the compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or treatment agent for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diabetes or syndrome X.

1 . A dihydronaphthalene derivative compound represented by formula (I)  
       
         
           
           
               
               
           
         
         (wherein X represents (1) bond, or (2)_C1-4 alkylene,  
         Y represents (1) —O—, or (2) —S—,  
         Z represents C1-4 alkylene,  
         A represents (1) —O—, or (2) —S—,  
         R 1  represents (1) COOR 5 , (2) CONH 2 , (3) CONHOH, (4) CH20H, (5) CHO, (6) 1H-tetrazol-5-yl, or (7) 3,5-dioxoisooxazolin-4-yl,  
         R 5  represents (1) hydrogen, or (2) C1-8 alkyl,  
         R 2  and R 3  each independently represents (1) hydrogen, (2) C1-8 alkyl (3) C1-8 alkoxy, or (4) C1-8 alkoxy substituted by a phenyl,  
         R 4  represents (1) hydrogen, or (2) C1-8 alkyl,  
         D represents D 1 , D 2 , or D 3 ,  
         D 1  represents  
         
           
             
             
                 
                 
             
           
         
         ring1 represents partially or fully optionally saturated C3-10 mono- or bi-carbocyclic aryl,  
         D2 represents  
         
           
             
             
                 
                 
             
           
         
         ring2 represents partially or fully optionally saturated 3-10 membered mono- or bi-heterocyclic aryl containing 1-4 hetero atom(s) selected from oxygen, nitrogen or sulfur atom,  
         D 3  represents C1-8 alkyl,  
         R 6  represents (1) hydrogen, (2) C1-8 alkyl, (3) nitro, (4) NR 7 R 8 , (5) halogen, (6) C1-8 alkoxy, (7) C1-8 alkylthio, (8) CF 3 , (9) CF 3 O, (10) partially or fully optionally saturated C3-10 mono- or bi-carbocyclic aryl, or (11) partially or fully optionally saturated 3-10 membered mono- or bi-heterocyclic aryl containing 1-4 hetero atom(s) selected from oxygen, nitrogen or sulfur atom,  
         R 7  and R 8  each independently represents (1) hydrogen atom, or (2) C1-alkyl,  
         m represents 1-3 g    
         or a nontoxic salt thereof.  
       
     
     
         2 . The dihydronaphthalene derivative compound according to  claim 1 , wherein D represents D 1 , and R 1  represents COOR 5 , or a nontoxic salt thereof.  
     
     
         3 . The dihydronaphthalene derivative compound according to  claim 1 , wherein D represents D 1 , and R 1  represents CONF 2 , CONHOH, CH 2 OH, CHO, 1H-tetrazol-5-yl or 3,5-dioxoisooxazolin-4-yl, or a nontoxic salt thereof.  
     
     
         4 . The dihydronaphthalene derivative compound according to  claim 1 , wherein D represents D 2 , and R 1  represents COOR 5 , or a nontoxic salt thereof.  
     
     
         5 . The dihydronaphthalene derivative compound according to  claim 1 , wherein D represents D 2 , and R 1  represents CONF 2 , CONROH, CH 2 OH, CHO, 1H-tetrazol-5-yl or 3,5-dioxoisooxazolin-4-yl, or a nontoxic salt thereof.  
     
     
         6 . The dihydronaphthalene derivative compound according to  claim 1 , wherein D represents D 3 , and R 1  represents COOR 5 , or a nontoxic salt thereof.  
     
     
         7 . The dihydronaphthalene derivative compound according to  claim 1 , wherein D represents D 3 , and R 1  represents CONH 2 , CONHOH, CH 2 OH, CHO, 1H-tetrazol-5-yl or 3,5-dioxoisooxazolin-4-yl, or a nontoxic salt thereof.  
     
     
         8 . The dihydronaphthalene derivative compound according to  claim 2 , which is 
 1) 3-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    2) 3-(5-(2-(2-phenyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    3) 3-(5-(2-(2-(4-t-butylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    4) 3-(5-(2-(2-(4-dimethylaminophenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    5) 3-(5-(2-(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    6) 3-(5-(2-(2-(4-trifluoromethyloxyphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    7) 3-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    8) 3-(5-(2-(2-(4-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    9) 3-(5-(2-(2-(4-methylthiophenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    10) 3-(5-(2-(2-(4-isopropylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    11) 3-(5-(2-(2-(4-propylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    12) 2-(5-(2-(2-phenyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetic acid ethyl ester,    13) 2-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetic acid ethyl ester,    14) 2-(5-(2-(2-(4-cyclohexylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetic acid ethyl ester,    15) 5-(5-(2-(2-phenyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)pentanoic acid methyl ester,    16) 5-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)pentanoic acid methyl ester,    17) 5-(5-(2-(2-(4-dimethylaminophenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)pentanoic acid methyl ester,    18) 2,2-dimethyl-3-(5-(2-(2-phenyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    19) 2,2-dimethyl-5-(5-(2-(2-phenyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)pentanoic acid methyl ester,    20) 2-benzyloxy-3-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    21) 3-(5-(2-(2-phenyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    22) 3-(5-(2-(2-(4-t-butylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    23) 3-(5-(2-(2-(4-dimethylaminophenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    24) 3-(5-(2-(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    25) 3-(5-(2-(2-(4-trifluoromethyloxyphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    26) 3-(5-(2-(2-(4-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    27) 3-(5-(2-(2-(4-methylthiophenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    28) 3-(5-(2-(2-(4-isopropylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    29) 3-(5-(2-(2-(4-propylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    30) 2-(5-(2-(2-phenyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetic acid,    31) 2-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetic acid,    32) 5-(5-(2-(2-phenyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)pentanoic acid,    33) 5-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)pentanoic acid,    34) 5-(5-(2-(2-(4-dimethylaminophenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)pentanoic acid,    35) 2,2-dimethyl-3-(5-(2-(2-phenyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    36) 2,2-dimethyl-5-(5-(2-(2-phenyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)pentanoic acid,    37) 2-benzyloxy-3-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    38) 2-ethoxy-3-(5-(2-(2-(4-cyclohexylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid, or    39) 2-ethoxy-3-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid, or a nontoxic salt thereof.    
     
     
         9 . The dihydronaphthalene derivative compound according to  claim 3 , which is 
 1) 2-(5-(2-(2-(4-cyclohexylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)ethanol,    2) 2-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)ethanol,    3) 3-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanol,    4) 2-(5-(2-(2-(4-cyclohexylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetaldehyde,    5) 2-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetaldehyde,    6) 2-ethoxy-3-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanamide,    7) N-hydroxy-3-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanamide,    8) N-hydroxy-2-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetamide,    9) 3-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanamide,    10) 5-(2-(5-(2-(5-methyl-2-(4-methylphenyl)oxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)ethyl)-1H-tetrazole, or    11) 4-((5-(2-(5-methyl-2-(4-methylphenyl)oxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)methyl)isooxazolidin-3,5-dione, or a nontoxic salt thereof.    
     
     
         10 . The dihydronaphthalene derivative compound according to  claim 4 , which is 
 1) 3-(5-(2-(2-(6-dimethylaminopyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    2) 3-(5-(2-(2-(1,3-dioxaindan-5-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    3) 3-(5-(2-(2-(6-(morpholin-4-yl)pyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    4) 3-(5-(2-(2-(2,2-difluoro-1,3-dioxaindan-5-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    5) 3-(5-(2-(2-(6-diethylaminopyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    6) 3-(5-(2-(2-(piperidin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    7) 3-(5-(2-(2-(4-methylpiperazin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    8) 3-(5-(2-(2-(morpholin-4-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    9) 3-(5-(2-(2-(thiomorpholin-4-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    10) 3-(5-(2-(2-(6-methylpyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    11) 3-(5-(2-(2-(1,5-dimethylpyrazol-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    12) 3-(5-(2-(2-(4-methylpiperidin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    13) 3-(5-(2-(2-(5-methylpyrazin-2-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    14) 3-(5-(2-(2-(1,2,3,6-tetrahydropyridin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    15) 2-(5-(2-(2-(4-methylpiperazin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetic acid ethyl ester,    16) 2-(5-(2-(2-(piperidin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetic acid ethyl ester,    17) 5-(5-(2-(2-(1,3-dioxaindan-5-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)pentanoic acid methyl ester,    18) 2,2-dimethyl-3-(5-(2-(2-(6-dimethylaminopyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    19) 2,2-dimethyl-3-(5-(2-(2-(6-(pyridin-1-yl)pyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    20) 2,2-dimethyl-3-(5-(2-(2-(6-(morpholin-4-yl)pyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    21) 2,2-dimethyl-3-(5-(2-(2-(6-methylpyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    22) 2,2-dimethyl-3-(5-(2-(2-(morpholin-4-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    23) 2,2-dimethyl-3-(5-(2-(2-(piperidin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    24) 2,2-dimethyl-3-(5-(2-(2-(thiomorpholin-4-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    25) 3-(5-(2-(2-(6-dimethylaminopyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    26) 3-(5-(2-(2-(1,3-dioxaindan-5-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    27) 3-(5-(2-(2-(6-(morpholin-4-yl)pyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    28) 3-(5-(2-(2-(2,2-difluoro-1,3-dioxaindan-5-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    29) 3-(5-(2-(2-(6-diethylaminopyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    30) 3-(5-(2-(2-(piperidin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    31) 3-(5-(2-(2-(4-methylpiperazin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    32) 3-(5-(2-(2-(morpholin-4-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    33) 3-(5-(2-(2-(thiomorpholin-4-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    34) 3-(5-(2-(2-(6-methylpyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    35) 3-(5-(2-(2-(1,5-dimethylpyrazol-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    36) 3-(5-(2-(2-(4-methylpiperidin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    37) 3-(5-(2-(2-(5-methylpyrazin-2-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    38) 3-(5-(2-(2-(1,2,3,6-tetrahydropyridin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    39) 5-(5-(2-(2-(1,3-dioxaindan-5-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)pentanoic acid,    40) 2,2-dimethyl-3-(5-(2-(2-(6-dimethylaminopyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    41) 2,2-dimethyl-3-(5-(2-(2-(6-(pyridin-1-yl)pyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    42) 2,2-dimethyl-3-(5-(2-(2-(6-(morpholin-4-yl)pyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid, 43) 2,2-dimethyl-3-(5-(2-(2-(6-methylpyridin-3-yl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    44) 2,2-dimethyl-3-(5-(2-(2-(morpholin-4-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    45) 2,2-dimethyl-3-(5-(2-(2-(piperidin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    46) 2,2-dimethyl-3-(5-(2-(2-(thiomorpholin-4-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    47) 2-ethoxy-3-(5-(2-(2-(4-methylpiperazin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid, or    48) 2-ethoxy-3-(5-(2-(2-(piperidin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid, or a nontoxic salt thereof.    
     
     
         11 . The dihydronaphthalene derivative compound according to  claim 5 , which is 
 1) 2-(5-(2-(2-(4-methylpiperazin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)ethanol,    2) 2-(5-(2-(2-(piperidin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)ethanol,    3) 2-(5-(2-(2-(4-methylpiperazin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetaldehyde, or    4) 2-(5-(2-(2-(piperidin-1-yl)-5-methylthiazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetaldehyde, or a nontoxic salt thereof.    
     
     
         12 . The dihydronaphthalene derivative compound according to  claim 6 , which is 
 1) 3-(5-(2-(2-isopropyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid ethyl ester,    2) 2-(5-(2-(2-isopropyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetic acid ethyl ester,    3) 2,2-dimethyl-3-(5-(2-(2-isopropyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid methyl ester,    4) 3-(5-(2-(2-isopropyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid,    5) 2,2-dimethyl-3-(5-(2-(2-isopropyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid, or    6) 2-ethoxy-3-(5-(2-(2-isopropyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)propanoic acid, or a nontoxic salt thereof.    
     
     
         13 . The dihydronaphthalene derivative compound according to  claim 7 , which is 
 1) 2-(5-(2-(2-isopropyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)ethanol, or    2) 2-(5-(2-(2-isopropyl-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalen-1-yl)acetaldehyde, or a nontoxic salt thereof.    
     
     
         14 . A peroxisome proliferator activated receptor (PPAR) regulator comprising a dihydronaphthalene derivative compound of formula (I) described in  claim 1 , or a nontoxic salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.  
     
     
         15 . A peroxisome proliferator activated receptor (PPAR) α and γ type regulator comprising a dihydronaphthalene derivative compound of formula (I) described in  claim 1 , or a nontoxic salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.  
     
     
         16 . A peroxisome proliferator activated receptor (PPAR) α and γ type agonist comprising a dihydronaphthalene derivative compound of formula (I) described in  claim 1 , or a nontoxic salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.  
     
     
         17 . A pharmaceutical composition for treatment or prevention of hypoglycemia and/or hypolipidemia comprising a dihydronaphthalene derivative compound of formula (I) described in  claim 1 , or a nontoxic salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.  
     
     
         18 . A pharmaceutical composition for treatment or prevention of diseases associated with metabolic disorders hyperlipidemia, atherosclerosis, hypertension, circulatory diseases, overeating or coronary heart diseases comprising a dihydronaphthalene derivative compound of formula (I) described in  claim 1 , or a nontoxic salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.  
     
     
         19 . An pharmaceutical composition for elevating an HDL cholesterol-lowering an LDL cholesterol and/or a VLDL cholesterol, or reducing risk factor of diabetes and/or syndrome X comprising a dihydronaphthalene derivative compound of formula (I) described in  claim 1 , or a nontoxic salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.  
     
     
         20 . The pharmaceutical composition according to  claim 18 , wherein said metabolic disorders are selected from the group consisting of diabetes, obesity, syndrome X, hypercholesterolemia and hyperlipoproteinemia.  
     
     
         21 . A method for treating or prevention of diseases associated with metabolic disorders, hyperlipidemia, atherosclerosis, hypertension, circulatory diseases, overeating or coronary heart diseases comprising administering to a subject an effective amount of a composition comprising a dihydronaphthalene derivative compound of formula (I) described in  claim 1 , or a nontoxic salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.  
     
     
         22 . The method according to  claim 21 , wherein said metabolic disorders are selected from the group consisting of diabetes, obesity, syndrome X, hypercholesterolemia and hyperlipoproteinemia.  
     
     
         23 . A method for elevating an HDL cholesterol, lowering an LDL cholesterol and/or a VLDL cholesterol, or reducing risk factor of diabetes and/or syndrome X comprising administering to a subject an effective amount of a composition comprising a dihydronaphthalene derivative compound of formula (I) described in  claim 1 , or a nontoxic salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.